{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:50:32Z","timestamp":1794484232079,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In case-control studies, a variety of factors have been associated with <jats:italic>Clostridioides difficile<\/jats:italic> infection (CDI) due to the epidemic ribotype 027 strain. However, many studies have been limited due to small sample size and inclusion of only one facility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using a nationwide cohort of hospitalized patients in the Veterans Affairs (VA) Healthcare System, we conducted a retrospective, 1:3 matched case-control study of patients with CDI due to the ribotype 027 strain versus non-027 strains from October 1, 2008, to September 30, 2020. Controls were matched to cases by health care facility and year of diagnosis. Multivariate logistic regression was used to identify risk factors for CDI due to the 027 strain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 3,353 cases were matched to 10,059 controls in 84 VA facilities. CDI due to the ribotype 027 strain was independently associated with prior macrolide or fluoroquinolone exposure, decreased functional capability, methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> nasal colonization, age &gt;65 years, white blood cell count &gt;11,000 cells\/mm<jats:sup>3<\/jats:sup>, and serum albumin &lt; 3.5 g\/dl.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Antimicrobial stewardship interventions focused on fluoroquinolones and macrolides could be beneficial in reducing the risk for infection due to the ribotype 027 <jats:italic>C. difficile<\/jats:italic> strain. Several other factors could potentially be used to identify patients at increased risk for CDI due to the ribotype 027 strain, but further studies are needed to assess their utility in clinical settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13756-025-01571-0","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T21:01:39Z","timestamp":1747429299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for Clostridioides difficile infection caused by ribotype 027 strains in the Veterans Affairs Healthcare System: a\u00a0matched case-control study"],"prefix":"10.1186","volume":"14","author":[{"given":"Sandra Y.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis J.","family":"Donskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa051590","volume":"353","author":"LC McDonald","year":"2005","unstructured":"McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433\u201341.","journal-title":"N Engl J Med."},{"key":"1571_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/ng.2478","volume":"45","author":"M He","year":"2013","unstructured":"He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45:109\u201313.","journal-title":"Nat Genet."},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1086\/521859","volume":"46 Suppl 1","author":"RC Owens Jr","year":"2008","unstructured":"Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S19-31.","journal-title":"Clin Infect Dis."},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1128\/AAC.01820-15","volume":"60","author":"JT Wieczorkiewicz","year":"2015","unstructured":"Wieczorkiewicz JT, Lopansri BK, Cheknis A, Osmolski JR, Hecht DW, Gerding DN, Johnson S. Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluoroquinolone- and macrolide-resistant epidemic C. difficile strain BI\/NAP1\/027. Antimicrob Agents Chemother. 2015;60:418\u201323.","journal-title":"Antimicrob Agents Chemother."},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1128\/AAC.01582-06","volume":"51","author":"DA Adams","year":"2007","unstructured":"Adams DA, Riggs MM, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother. 2007;51:2674\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1473-3099(17)30052-X","volume":"17","author":"CJ Donskey","year":"2017","unstructured":"Donskey CJ. Fluoroquinolone restriction to control fluoroquinolone-resistant Clostridium difficile. Lancet Infect Dis. 2017;17:353\u20134.","journal-title":"Lancet Infect Dis."},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/522654","volume":"45","author":"CA Muto","year":"2007","unstructured":"Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive \u201cbundle\u201d approach. Clin Infect Dis. 2007;45:1266\u201373.","journal-title":"Clin Infect Dis."},{"key":"1571_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1086\/595694","volume":"30","author":"AJ Kallen","year":"2009","unstructured":"Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30:264\u201372.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jhin.2015.05.013","volume":"91","author":"JB Sarma","year":"2015","unstructured":"Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T, Woolfrey S. Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis. J Hosp Infect. 2015;91:74\u201380.","journal-title":"J Hosp Infect."},{"key":"1571_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1473-3099(16)30397-8","volume":"17","author":"T Lawes","year":"2016","unstructured":"Lawes T, Lopez-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Wares KD, Sinclair C, et al. Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis. Lancet Infect Dis. 2016;17:194\u2013206.","journal-title":"Lancet Infect Dis."},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","volume":"17","author":"KE Dingle","year":"2017","unstructured":"Dingle KE, Didelot X, Phuong Quan T, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17:411\u201321.","journal-title":"Lancet Infect Dis."},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/cid\/cir549","volume":"53","author":"A Goorhuis","year":"2011","unstructured":"Goorhuis A, Debast SB, Dutilh JC, et al. Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. Clin Infect Dis. 2011;53:860\u20139.","journal-title":"Clin Infect Dis."},{"key":"1571_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1017\/ice.2014.45","volume":"36","author":"T Scardina","year":"2015","unstructured":"Scardina T, Labuszewski L, Pacheco SM, Adams W, Schreckenberger P, Johnson S. Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1\/BI\/027 strain in a non-epidemic setting. Infect Control Hosp Epidemiol. 2015;36:280\u20136.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"1571_CR14","doi-asserted-by":"publisher","first-page":"ofz433","DOI":"10.1093\/ofid\/ofz433","volume":"6","author":"NS Mani","year":"2019","unstructured":"Mani NS, Lynch JB, Fang FC, Chan JD. Risk Factors for BI\/NAP1\/027 Clostridioides difficile infections and clinical outcomes compared with non-NAP1 strains. Open Forum Infect Dis. 2019;6:ofz433.","journal-title":"Open Forum Infect Dis."},{"key":"1571_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-008-0564-9","volume":"27","author":"L Fenner","year":"2008","unstructured":"Fenner L, Frei R, Gregory M, Dangel M, Stranden A, Widmer AF. Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006\u20132007. Eur J Clin Microbiol Infect Dis. 2008;27:1201\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"1571_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhin.2009.02.020","volume":"72","author":"F Sundram","year":"2009","unstructured":"Sundram F, Guyot A, Carboo I, Green S, Lilaonitkul M, Scourfield A. Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect. 2009;72:111\u20138.","journal-title":"J Hosp Infect."},{"key":"1571_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1017\/ice.2020.383","volume":"42","author":"SY Silva","year":"2021","unstructured":"Silva SY, Wilson BM, Redmond SN, Donskey CJ. Inpatient fluoroquinolone use in Veterans\u2019 Affairs hospitals is a predictor of Clostridioides difficile infection due to fluoroquinolone-resistant ribotype 027 strains. Infect Control Hosp Epidemiol. 2021;42:57\u201362.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"1571_CR18","doi-asserted-by":"publisher","first-page":"115308","DOI":"10.1016\/j.diagmicrobio.2021.115308","volume":"100","author":"CA Gentry","year":"2021","unstructured":"Gentry CA, Williams RJ 2nd, Campbell D. Continued decline in the prevalence of the Clostridioides difficile BI\/NAP1\/027 strain across the United States Veterans Health Administration. Diagn Microbiol Infect Dis. 2021;100:115308.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"1571_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1017\/ice.2023.18","volume":"44","author":"LK Kociolek","year":"2023","unstructured":"Kociolek LK, Gerding DN, Carrico R, et al. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44:527\u201349.","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"9","key":"1571_CR20","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1128\/AAC.00146-08","volume":"52","author":"AC Labb\u00e9","year":"2008","unstructured":"Labb\u00e9 AC, Poirier L, Maccannell D, et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI\/NAP1\/027 strain. Antimicrob Agents Chemother. 2008;52(9):3180\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"1571_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/wvn.12526","volume":"18","author":"E Lovicu","year":"2021","unstructured":"Lovicu E, Faraone A, Fortini A. Admission braden scale score as an early independent predictor of in-hospital mortality among inpatients with COVID-19: a retrospective cohort study. Worldviews Evid Based Nurs. 2021;18(5):247\u201353.","journal-title":"Worldviews Evid Based Nurs."},{"issue":"6","key":"1571_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/jgs.14801","volume":"65","author":"B Bandle","year":"2017","unstructured":"Bandle B, Ward K, Min SJ, et al. Can braden score predict outcomes for hospitalized heart failure patients? J Am Geriatr Soc. 2017;65(6):1328\u201332.","journal-title":"J Am Geriatr Soc."},{"key":"1571_CR23","doi-asserted-by":"publisher","unstructured":"Reveles KR, Strey KA, Albuquerque EL, Jacota D, Jones X, Carreno JJ. Retrospective, propensity score matched study examining relationship between frailty and Clostridioides difficile infection in a National Cohort of United States Veterans. Am J Infect Control. 2024:S0196-6553(24)00687-4. https:\/\/doi.org\/10.1016\/j.ajic.2024.08.020.","DOI":"10.1016\/j.ajic.2024.08.020"},{"issue":"1","key":"1571_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.idc.2014.11.001","volume":"29","author":"CJ Donskey","year":"2015","unstructured":"Donskey CJ, Kundrapu S, Deshpande A. Colonization versus carriage of Clostridium difficile. Infect Dis Clin North Am. 2015;29(1):13\u201328.","journal-title":"Infect Dis Clin North Am."},{"issue":"2","key":"1571_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3201\/eid2602.181965","volume":"26","author":"AM Skinner","year":"2020","unstructured":"Skinner AM, Petrella L, Siddiqui F, Sambol SP, Gulvik CA, Gerding DN, Donskey CJ, Johnson S. Unique clindamycin-resistant Clostridioides difficile strain related to fluoroquinolone-resistant epidemic BI\/RT027 strain. Emerg Infect Dis. 2020;26(2):247\u201354.","journal-title":"Emerg Infect Dis."},{"issue":"12","key":"1571_CR26","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/cid\/ciu203","volume":"58","author":"SK Lim","year":"2014","unstructured":"Lim SK, Stuart RL, Mackin KE, et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis. 2014;58(12):1723\u201330.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"1571_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.20411\/pai.v4i2.327","volume":"4","author":"SN Redmond","year":"2019","unstructured":"Redmond SN, Silva SY, Wilson BM, Cadnum JL, Donskey CJ. Impact of reduced fluoroquinolone use on Clostridioides difficile infections resulting from the fluoroquinolone-resistant ribotype 027 strain in a Veterans Affairs medical center. Pathog Immun. 2019;4(2):251\u20139.","journal-title":"Pathog Immun."},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2334-11-187","volume":"11","author":"NL Werner","year":"2011","unstructured":"Werner NL, Hecker MT, Sethi AK, Donskey CJ. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis. 2011;11:187.","journal-title":"BMC Infect Dis."}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-025-01571-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T21:01:40Z","timestamp":1747429300000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-025-01571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1186\/s13756-025-01571-0","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"C.J.D has received research grants from Clorox and Pfizer unrelated to the current study. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}